1. Home
  2. PRPO vs BREA Comparison

PRPO vs BREA Comparison

Compare PRPO & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • BREA
  • Stock Information
  • Founded
  • PRPO N/A
  • BREA 2022
  • Country
  • PRPO United States
  • BREA Ireland
  • Employees
  • PRPO 57
  • BREA N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • BREA Services-Misc. Amusement & Recreation
  • Sector
  • PRPO Industrials
  • BREA Consumer Discretionary
  • Exchange
  • PRPO Nasdaq
  • BREA Nasdaq
  • Market Cap
  • PRPO 9.5M
  • BREA 10.0M
  • IPO Year
  • PRPO N/A
  • BREA 2023
  • Fundamental
  • Price
  • PRPO $6.59
  • BREA $1.10
  • Analyst Decision
  • PRPO
  • BREA
  • Analyst Count
  • PRPO 0
  • BREA 0
  • Target Price
  • PRPO N/A
  • BREA N/A
  • AVG Volume (30 Days)
  • PRPO 7.9K
  • BREA 3.5M
  • Earning Date
  • PRPO 11-11-2024
  • BREA 11-23-2024
  • Dividend Yield
  • PRPO N/A
  • BREA N/A
  • EPS Growth
  • PRPO N/A
  • BREA N/A
  • EPS
  • PRPO N/A
  • BREA N/A
  • Revenue
  • PRPO $16,719,999.00
  • BREA $1,268,367.00
  • Revenue This Year
  • PRPO $75.18
  • BREA N/A
  • Revenue Next Year
  • PRPO N/A
  • BREA N/A
  • P/E Ratio
  • PRPO N/A
  • BREA N/A
  • Revenue Growth
  • PRPO 52.61
  • BREA 606.55
  • 52 Week Low
  • PRPO $4.31
  • BREA $0.51
  • 52 Week High
  • PRPO $8.99
  • BREA $3.00
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 52.82
  • BREA 66.97
  • Support Level
  • PRPO $6.42
  • BREA $0.58
  • Resistance Level
  • PRPO $6.99
  • BREA $1.34
  • Average True Range (ATR)
  • PRPO 0.33
  • BREA 0.15
  • MACD
  • PRPO -0.04
  • BREA 0.05
  • Stochastic Oscillator
  • PRPO 69.91
  • BREA 45.57

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About BREA Brera Holdings PLC

Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.

Share on Social Networks: